

Synthesis of 4,5-disubstituted-2-thioxo-1,2,3,4-tetrahydropyrimidines and investigation of their acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase I/II inhibitory and antioxidant activities

Emin Garibov, Parham Taslimi, Afsun Sujayev, Zeynebe Bingol, Songul Çetinkaya, İlhami Gulçin, Sukru Beydemir, Vagif Farzaliyev, Saleh H. Alwasel & Claudiu T. Supuran

To cite this article: Emin Garibov, Parham Taslimi, Afsun Sujayev, Zeynebe Bingol, Songul Çetinkaya, İlhami Gulçin, Sukru Beydemir, Vagif Farzaliyev, Saleh H. Alwasel & Claudiu T. Supuran (2016): Synthesis of 4,5-disubstituted-2-thioxo-1,2,3,4-tetrahydropyrimidines and investigation of their acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase I/II inhibitory and antioxidant activities, Journal of Enzyme Inhibition and Medicinal Chemistry, DOI: [10.1080/14756366.2016.1198901](https://doi.org/10.1080/14756366.2016.1198901)

To link to this article: <http://dx.doi.org/10.1080/14756366.2016.1198901>



Published online: 22 Jun 2016.



Submit your article to this journal [↗](#)



Article views: 9



View related articles [↗](#)



View Crossmark data [↗](#)



RESEARCH ARTICLE

Synthesis of 4,5-disubstituted-2-thioxo-1,2,3,4-tetrahydropyrimidines and investigation of their acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase I/II inhibitory and antioxidant activities

Emin Garibov¹, Parham Taslimi², Afsun Sujayev¹, Zeyne Bingol², Songul Çetinkaya², İlhami Gülçin^{2,3}, Sukru Beydemir², Vagif Farzaliyev¹, Saleh H. Alwasel², and Claudiu T. Supuran^{4,5}

¹Laboratory of Theoretical Bases of Synthesis and Action Mechanism of Additives, Institute of Chemistry of Additives, Azerbaijan National Academy of Sciences, Baku, Azerbaijan, ²Department of Chemistry, Faculty of Sciences, Atatürk University, Erzurum, Turkey, ³Department of Zoology, College of Science, King Saud University, Riyadh-Saudi, Arabia, ⁴Dipartimento Di Chimica Ugo Schiff, Università Degli Studi Di Firenze, Firenze, Sesto Fiorentino, Italy, and ⁵Neurofarba Department, Section of Pharmaceutical and Nutraceutical Sciences, Università Degli Studi Di Firenze, Florence, Sesto Fiorentino, Italy

Abstract

A series of tetrahydropyrimidinethiones were synthesized from thiourea, β -diketones and aromatic aldehydes, such as p-tolualdehyde, p-anisaldehyde, o-tolualdehyde, salicylaldehyde and benzaldehyde. These cyclic thioureas showed good inhibitory action against acetylcholine esterase (AChE), butyrylcholine esterase (BChE), and human (h) carbonic anhydrase (CA) isoforms I and II. AChE and BChE inhibitions were in the range of 6.11–16.13 and 6.76–15.68 nM, respectively. hCA I and II were effectively inhibited by these compounds, with K_i values in the range of 47.40–76.06 nM for hCA I, and of 30.63–76.06 nM for hCA II, respectively. The antioxidant activity of the cyclic thioureas was investigated by using different *in vitro* antioxidant assays, including 1,1-diphenyl-2-picrylhydrazyl (DPPH·) radical scavenging, Cu^{2+} and Fe^{3+} reducing, and Fe^{2+} chelating activities.

Keywords

Acetylcholinesterase, antioxidant activity, butyrylcholinesterase, carbonic anhydrase, enzyme inhibition

History

Received 19 April 2016
Revised 1 June 2016
Accepted 4 June 2016
Published online 21 June 2016

Introduction

Recently, the synthesis of some pyrimidine thiones derivatives attracted great attention due to their biological and pharmaceutical properties including analgesic, anti-staphylococcal, antiviral, anti-tuberculosis, anti-fungal, and efficacy against some cardiovascular diseases¹. A facile synthesis of these compounds includes Biginelli reaction, when aliphatic/aromatic aldehydes, urea/thiourea, acetylacetone, and various catalysts lead to the ring closure with the formation of the desired heterocycle. One major factor influencing the outcome and yields in the desired products is the selection of the catalyst for Biginelli's reaction.² Synthesis of 3,4-dihydropyrimidine-2(1H) thiones in a simple and useful way is based on this one-pot, three-component condensation of aldehydes, methylene active compounds and thiourea in acidic media.^{1,2}

The reversible hydration of carbon dioxide (CO_2) to form bicarbonate (HCO_3^-) and protons (H^+) is a simple but very important chemical reaction that can be performed by various classes of carbonic anhydrases (CAs, EC 4.2.1.1).^{3–6} The interconversion of CO_2 and HCO_3^- is spontaneously balanced to maintain the equilibrium between dissolved inorganic CO_2 , the highly unstable carbonic acid (H_2CO_3) and carbonate (CO_3^{2-}) of which HCO_3^- is physiologically the most important species

(due to the physiological pH values). Indeed, bicarbonate is a substrate for several carboxylation enzymes involved in biosynthetic pathways such as biosynthesis of urea, glucose, fatty acids and possibly nucleotides^{7–10}. The reaction not only provides a means to control the physiological pH values, but also supplies HCO_3^- ions for various physiological processes or metabolic, biosynthetic pathways, as those mentioned above^{11–14}. So far, six unrelated genetic CA families have been discovered, namely, the α -, β -, γ -, δ -, ζ - and η -CAs. In many organisms, a large number of isoforms of the CA family are present, which possess specialized functions in various tissues and organs^{15–19}. These CA families are found in most living organisms. For example α -CAs are found in humans and other mammals and divided into four broad subgroups, which, in turn consist of several isoforms: the cytosolic CAs (CA I, II, III, VII, and XIII), mitochondrial CAs (CA VA and VB), secreted CA (CA VI), as well as membrane-associated CAs (CA IV, IX, XII, XIV and XV)^{20–24}. There are three additional, acatalytic CA isoforms (CA VIII, X, and XI) whose functions remain unclear. On the other hand, it was reported that β -CAs exist in most prokaryotes and plant chloroplasts, γ -CAs are present in methanogens and most bacteria. δ -CAs and ζ -CAs were found in diatoms²⁵. Recently, the η -CA family was identified in organisms of the genus *Plasmodium*. These enzymes previously thought to belong to the α -CA family, were shown to possess unique features such as their metal ion coordination pattern^{26–29}, which motivates their designation as a new genetic family, i.e., the η -CAs. As such, CA inhibitors (CAIs)

Address for correspondence: Prof. Dr. İlhami Gülçin, Department of Chemistry, Faculty of Science, Atatürk University, 25240- Erzurum, Turkey. E-mail: igulcin@atauni.edu.tr

have a role as pharmaceutical agents in the treatment of various pathophysiological conditions^{30–33}. CAIs possessing different inhibition mechanisms compared to the classical inhibitors were reported in the last years^{34,35}. The interest in CAIs is mainly motivated by their pharmacological properties and clinical use as diuretics, antiglaucoma, antiobesity or antiepileptic agents, as well as anticancer agents and diagnostic tools^{36–38}.

The neurotransmitter acetylcholine (ACh) mediates its physiological effects via a plethora of receptors expressed throughout the central nervous system and the peripheral nervous system^{39,40}. Elder persons suffering from Alzheimer's disease (AD) have a low ACh level in the hippocampus and cortex, which is the main cause of AD^{17,41}. Acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) are serine hydrolases that catalyze the hydrolysis of acetylcholine, thus regulating cholinergic neurotransmission^{42–44}. It is well known that both enzymes are two major forms of cholinesterases in mammalian tissues. AChE is highly active for the hydrolysis of acetylcholine (ACh) and can regulate the concentration of ACh, which plays a key role in memory and learning as a central neurotransmitter^{45,46}. On the other hand, BChE is an endogenous enzyme synthesized by the liver, which serves as a catalyzer for the hydrolysis of esters in choline⁴⁷. In general, AChE displays a greater affinity for ACh and thus has greater activity for its hydrolysis as compared to BChE. Studies indicate that in the case of AD, the level of AChE in certain brain regions is significantly reduced and the BChE level is progressively increased, which is responsible for the level of ACh. In fact, a portion of evidence suggests that the inhibition of BChE can raise ACh levels and improves cognition in AD. Currently, the most efficacious treatment approaches for AD are four cholinesterase inhibitors including tacrine, rivastigmine, donepezil and galantamine^{48,49}.

All aerobic organisms have antioxidant defenses against free radicals and reactive oxygen species (ROS), including antioxidant enzymes and antioxidant food constituents to remove or repair the damaged molecules^{50–52}. Antioxidant compounds can scavenge free radicals or ROS and increase shelf life by retarding the process of lipid peroxidation, which is one of the major reasons for deterioration of food and pharmaceutical products during processing and storage^{53–55}. Also, they protect the human body from hazardous effects of free radicals and ROS. They retard the progress of many chronic diseases as well as lipid peroxidation. Hence, a need has appeared to identify alternative safe sources of antioxidants^{56,57}. Antioxidants are often added to foods and pharmaceuticals for preservation from the radical chain reactions. They act by inhibiting the initiation and propagation steps of radical chain reactions. Thus they lead the termination of the reaction and delay the oxidation process^{58,59}. At the present time, the most commonly used antioxidants are butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propylgallate, and *tert*-butyl hydroquinone^{60–62}. However, BHA and BHT have been restricted by legislative rules due to doubts over their toxic and carcinogenic effects^{63,64}. Therefore, there is a growing interest in natural and safer antioxidants for food applications, and a growing trend in consumer preferences towards natural antioxidants, all of which have given impetus to the attempts to explore new and safer sources of antioxidants^{65–67}.

The interest on the synthesis of new such heterocyclic compounds, containing multifunctional nitrogen and sulfur atoms within the ring, and their application as antimicrobial and antioxidant agents⁶⁸, prompted us to design the new cyclic thioureas (**1–8**), which were obtained for the first time by us based on using trifluoroacetic acid (TFAA) as catalyst (Figure 1).

In the present study we describe the design, synthesis and evaluation of some of cyclic thioureas (**1–8**) as effective acetylcholinesterase, butyrylcholinesterase, human carbonic

anhydrase inhibitor and antioxidant agents. Another main goal of this study, is compared their activities to related standard compounds including tacrine (for acetylcholinesterase and butyrylcholinesterase), acetazolamide (for human carbonic anhydrase isoenzymes I and II) and BHA, BHT, α -tocopherol and trolox (for antioxidant activities).

Experimental

Chemistry

Synthesis of 2-(methacryloyloxy)ethyl 6-methyl-2-thioxo-4-(p-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1)

Thiourea (0.76 g, 0.01 mol) was added to the solution of acetylacetone (5 mL) in ethyl alcohol (1 mL) and then 2-(methacryloyloxy) ethyl acetoacetate (1.91 mL, 0.01 mol) was added to the solution dropwise. After the mixture was stirred for 5 minutes, *p*-tolualdehyde (1.18 mL, 0.01 mol) was added and it was stirred for 30 min. Then TFAA (0.02 mL) was added to the reaction mixture and it was stirred by heating at 70–75 °C. The progress of the reaction was controlled by Sulifol UV 254 plate. After determining the full completion of reaction, solution was evaporated and is cleansed in ethyl alcohol solution. The white crystalline having the melting temperature of 212 °C is obtained. The yield is 1.8 g.

Eluent-ethanol: hexane (5:2). ¹H NMR (300 MHz, (DMSO-*d*₆, δ): 2.27 (s, 3H, CH₃); 4.49 (d, 2H, CH₂O); 5.06–5.17 (dd, 2H, CH₂); 5.78 (m, 1H, =CH); 7.25 (d, 2H, 2CH-Ar); 7.30 (t, 2H, 2CH-Ar); 7.77 (s, 1H, NH); 9.26 (1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) 18.34, 54.32, 64.18, 99.25, 117.43, 126.70, 127.79, 128.91, 133.43, 145.10, 149.56, 152.53, 165.38. IR ν , cm⁻¹: 3175 (NH), 1709 (C=O), 1092 (C=S), 756, 852, 974, 1230 (CH), 1608 (C=C).

Synthesis of 1-(4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (2)

Synthesis of 1-(4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (**2**) was realized according to the general procedure at 2.1 according to the literature⁶⁹. ¹H NMR data are in agreement with data given in the literature⁷⁰. ¹³C NMR (75 MHz, DMSO-*d*₆) 10.01, 19.33, 21.11, 30.19, 48.26, 54.01, 126.82, 129.50, 137.64, 141.76, 152.58, 194.78. IR ν , cm⁻¹: 1810–1951, 3000–3100 (Ar), 1493 (Ar C-H), 1614 (Ar C-C), 703 (CH), 1675, 1703 (C=O), 3257 (NH), 1236 (C=S).

Synthesis of ethyl 6-methyl-2-thioxo-4-(o-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (3)

Compound **3** was also synthesized following the procedure above and its ¹H- and ¹³C-NMR data are in agreement with data given in the literature⁷¹.

Synthesis of ethyl 4-(2-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (4)

Synthesized according to the general procedure at given above⁷². ¹H NMR data are in agreement with data given in the literature⁷². ¹³C NMR (75 MHz, DMSO-*d*₆) 14, 15, 48, 61, 104, 115, 121, 122, 128, 154, 160, 167, 180. IR ν , cm⁻¹: 3370–3040 (NH), 1709 (C=O), 1092 (C=S), 756, 852, 974, 1230 (CH), 1608 (C=C).

Synthesis of allyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (5)

Compound **5** was synthesized according to the procedure described above ("Synthesis of 2-(methacryloyloxy)ethyl




Figure 1. Chemical formula cyclic thioureas 1–8.

6-methyl-2-thioxo-4-(*p*-tolyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1)’’ section). White crystalline. M.p: 198 °C. ¹H NMR (300 MHz, (DMSO-*d*₆, δ): 1.79 (s, 3H, CH₃); 2.22 (s, 3H, CH₃); 4.19 (d, 2H, CH₂O); 5.12 (d, 1H, CH-Ar); 5.63–5.92 (s-s, 2H, =CH₂); 7.20 (m, 5H, 5CH-Ar); 9.75 (s, 1H, NH); 9.19 (s, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆) 15.5, 54.6, 55.8, 67.8, 106, 114, 116, 127, 133, 135, 158, 167, 180. IR ν, cm⁻¹: 3370–3040 (NH), 1635–1630 (C=O), 1092 (C=S), 756, 852, 974, 1230 (CH), 1607–1608 (C=C).

Synthesis of allyl 4-(2-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (6)

Compound **6** was synthesized as described above the section ‘‘Synthesis of 1-(4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (2)’’. M.p: 210 °C. ¹H NMR (300 MHz, (DMSO-*d*₆, δ): 1.75 (s, 3H, CH₃); 4.67 (d, 2H, CH₂O); 5.21–5.41 (dd, 2H, =CH₂); 5.89 (m, 1H, =CH); 6.78 (d, 1H, CH-Ar); 6.90 (d, 1H, CH-Ar); 7.19 (t, 2H, CH-Ar); 7.65 (s, 1H, NH); 9.64 (s, 1H, NH); 9.83 (H, OH). ¹³C NMR (75 MHz, DMSO-*d*₆) 24.43, 29.79, 48.16, 65.28, 83.51, 117.01, 118.26, 120.96, 125.84, 129.12, 132.71, 151.06, 155.00, 168.57. IR ν, cm⁻¹: 1618, 1560, 1526 (Ar), 3112 (CH₂=C), 785 (Ar-CH), 1722, 1701 (C(O)R), 1377, 1370 (CH₃), 1651 (C=C), 3242 (NH), 1314 (C-N).

Synthesis of 1-(4-(2-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (7) and Allyl 6-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (8)

The compounds **7** and **8** were also synthesized according to above procedure and their ¹H- and ¹³C-NMR data are in agreement with data given in the literature^{73,74}.

Enzymes studies

CA isoenzymes (hCA I, and II) were purified by sepharose-4B-L-tyrosine-sulfanilamide affinity chromatography in a single purification step⁷⁵. Sepharose-4B-L-tyrosine-sulfanilamide was prepared according to a reported method⁷⁶. Thus, pH of the

solution was adjusted to 8.7, using solid Tris. Then, supernatant was transferred to the previously prepared Sepharose-4B-L-tyrosine-sulphanilamide affinity column⁷⁷. Subsequently, the proteins from the column were spectrophotometrically determined at 280 nm⁷⁸. For determination of the purity of the hCA isoenzymes, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)⁷⁹, having 10 and 3% acrylamide as an eluent and packing gel, respectively, with 0.1% SDS⁸⁰ was performed, through which a single band was observed for each isoenzyme.

CA isoenzymes activities were determined according to the methods described by Verpoorte et al.⁸¹ and the methods reported previously⁸². Absorbance change at 348 nm from *p*-nitrophenylacetate (NPA) to *p*-nitrophenolate (NP) was recorded by 3 min intervals at the room temperature (25 °C) using a spectrophotometer (Shimadzu, UV-VIS Spectrophotometer, UVmini-1240, Kyoto, Japan). Quantity of the protein was measured spectrophotometrically at 595 nm during the purification steps according to the Bradford method⁸³ as reported previously. Bovine serum albumin was used as a standard protein. An activity (%)-[Cyclic thioureas] graph was depicted to determine the inhibition effect of each cyclic thioureas. For *K_i* values, three different cyclic thioureas were tested. NPA was used as a substrate at five different concentrations, and Lineweaver–Burk curves⁸⁴ were drawn as described previously⁸⁵.

In the third part of this study, the inhibitory effects of cyclic thioureas (**1–8**) on AChE and BChE activities were determined according to the Ellman test.⁸⁶ Acetylthiocholine iodide (AChI) or butyrylthiocholine iodide (BChI) were used as substrates for both reactions. 5,5'-Dithio-bis(2-nitro-benzoic)acid (DTNB) was used for the measurement of the AChE/BChE activities. Briefly, 100 mL of Tris/HCl buffer (1.0 M and pH 8.0), 10 mL of cyclic thioureas (**1–8**) solution dissolved in deionized water at different concentrations and 50 mL AChE/BChE (5.32 10⁻³ EU) solution were mixed and incubated for 10 min at 25 °C. Then a portion of DTNB (50 mL, 0.5 mM) was added. Subsequently, the reaction was initiated by the addition of 50 mL of AChI/BChI (10 mM). The hydrolysis of these AChI/BChI was monitored spectrophotometrically by the formation of yellow 5-thio-2-nitrobenzoate anion as the result of the reaction of DTNB with thiocholine,

released by the enzymatic hydrolysis of AChI/BChI, at a wavelength of 412 nm⁴⁸. For determination of the effects of cyclic thioureas (**1–8**) on AChE/BChE, cyclic thioureas (**1–8**) concentrations were added into the reaction solution. AChE/BChE activities were measured, and an experiment in the absence of drug was used as control. The IC₅₀ values were obtained from activity (%) versus cyclic thioureas (**1–8**) concentration plots. For determination of *K_i* values in the media with cyclic thioureas (**1–8**) as inhibitor, different ACh/BCh concentrations were used as substrates.

Determination of antioxidant activities

Fe³⁺ reducing ability of cyclic thioureas (**1–8**), Fe³⁺(CN)[−]₆ to Fe²⁺(CN)[−]₆ reduction method was used⁸⁷. Briefly, various concentrations of cyclic thioureas (**1–8**) (10–30 µg/mL) in 0.75 mL of deionized H₂O were added with 1.25 mL of phosphate buffer (0.2 M, pH 6.6) and 1.25 mL of potassium ferricyanide [K₃Fe(CN)₆] (1%)⁸⁸. Then, the solution was incubated at 50 °C during 20 min. After incubation period, trichloroacetic acid was added (1.25 mL, 10%). Lastly, a portion of FeCl₃ (0.5 mL, 0.1%) was transferred to this mixture and the absorbance value was enrolled at 700 nm in a spectrophotometer^{89,90}. According to the obtained results, when reduction capability increases, absorbance indicates greater value⁹¹.

Cu²⁺ reducing capability was performed according to the previous studies^{92–94}. For this purpose, aliquots of CuCl₂ solution (0.25 mL, 0.01 M), ethanolic neocuproine solution (0.25 mL, 7.5 × 10^{−3} M) and NH₄Ac buffer solution (0.25 mL, 1.0 M) were transferred to a test tube, which contains cyclic thioureas (**1–8**) at different concentrations (10–30 µg/mL). Total volume was completed with distilled H₂O to 2 mL and shaken vigorously. Absorbance of samples was recorded at 450 nm after 30 min⁹⁵.

Metal chelating ability of cyclic thioureas (**1–8**) was predicted according to previous studies^{96–98}. Fe²⁺-binding capacity of cyclic thioureas (**1–8**) was spectrophotometrically recorded at 562 nm. In brief, to a mixture of FeCl₂ (0.1 mL, 0.6 mM) cyclic thioureas (**1–8**) were added at three different concentrations (10–20 µg/mL) in methanol (0.4 mL). The reactions were started by Ferrozine (3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p'-disulfonic acid sodium salt) solution addition (0.1 mL, 5 mM). After that, the solution was mixed and incubated at room temperature for 10 min. Finally, absorbance value of the mixture was quantified spectrophotometrically at 562 nm versus blank sample^{99,100}.

DPPH· radical scavenging activity was performed according to our previous studies^{101–103}. The solution of DPPH· was prepared daily, stored in a flask coated with aluminum foil and kept in the dark at 4 °C. In brief, fresh solution of DPPH· (0.1 mM) was prepared in ethanol¹⁰⁴. Then, 1.5 mL of each cyclic thiourea (**1–8**) in ethanol was added an aliquot of this solution (0.5 mL) (10–30 µg/mL). These mixtures were mixed vigorously and incubated in the dark for 30 min. Finally the absorbance value was recorded at 517 nm in a spectrophotometer¹⁰⁵.

Results and discussion

The synthesis of compounds **1–8** was reported in Scheme 1. The synthesis of cyclic thioureas related to the title compounds has been reported in the literature^{69–73}. By a similar approach, the reaction of substituted p-tolualdehyde, p-anisaldehyde, o-tolualdehyde, salicylaldehyde and benzaldehyde with methylene active compounds such as β-diketones and thiourea in the presence of TFAA led to the desired cyclic thioureas (**1–8**). The three-component condensation reactions occurred within 2.5–3.0 h, at 60–75 °C. The synthesized compounds were crystalline and their structures were confirmed by IR, ¹H-, and ¹³C-NMR spectroscopy


techniques and elemental analysis. Valence vibrations of NH bond in IR spectrum of synthesized compounds (**1–8**) were observed in 3370–3040 cm^{−1} regions. Valence vibrations of the C=O bond in acetyl group are compatible with 1635–1630 cm^{−1} band.

Only some functional groups differ in their appearance. Carbon atoms in molecule in the ¹³C NMR spectrum of the same compounds have the following signals according to their electronic densities: 24, 29, 37, 51, 86, 117, 122, 125, 129, 132, 141, 151, 179 (C=S), 205 (C=O) ppm. It is known from the reaction mechanism that, enol form of aceto-acetic ether takes part in the reaction.

Biological activities

Here, we report the inhibition effect of cyclic thioureas (**1–8**) on two catalytically active hCA I, and II as well as against AChE, and BChE. Also, antioxidant activity of cyclic thioureas (**1–8**) was studied using four different antioxidant methods, including 1,1-diphenyl-2-picrylhydrazyl (DPPH·) radical scavenging, Cu²⁺ and Fe³⁺ reducing, and Fe²⁺ chelating activities. We discovered nanomolar inhibition against these metabolic enzymes. Cyclic thioureas **1**, **4** and **8**, which possesses a phenolic moiety in its scaffolds demonstrated effective antioxidant activities. The enzymes inhibition and antioxidant activities data of cyclic thioureas (**1–8**) reported here are shown in Tables 1–3, and the following comments can be drawn from these data:

- (1) The cytosolic isoenzymes CA I, and II are examined in this study. Cytosolic hCA I isoenzyme is ubiquitously expressed in body, and available in high concentrations in blood and gastrointestinal tract¹⁰⁶. It was demonstrated that CA I is involved in retinal and cerebral edema. Also, inhibition of CA I could be a valuable tool for fighting the condition¹⁰⁷. It is generally accepted that if *K_i* value of a tested compound is less than 50 µM (*K_i* > 50 µM), that compound is considered to be inactive against hCA I¹⁰⁸. The results presented in Table 1 indicate that cyclic thioureas (**1–8**) had effective inhibition profile against slow cytosolic hCA I isoform, and cytosolic dominant rapid hCA II isoenzyme. The cytosolic hCA I isoenzyme was inhibited by cyclic thioureas (**1–8**) in low nanomolar levels, the *K_i* of which differed between 47.40 ± 4.43 and 77.68 ± 3.69 nM. On the other hand, acetazolamide (AZA), considered being a broad-specificity CA inhibitor owing to its widespread inhibition of CAs, showed *K_i* value of 289.22 ± 2.60 nM against hCA I. Among



Scheme 1. The synthesis route of the new cyclic thioureas (**1–8**).

the inhibitors, 1-(4-(2-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (**7**) was found to be the best hCA I inhibitor with K_i of 47.40 ± 4.43 nM. The hCA I inhibition effects of all cyclic thioureas (**1–8**) were found to be the greater than that of acetazolamide, which was a clinically standard CA inhibitor.

- (2) CA II, which generally exists in red blood cells in lower concentrations in mammals, has approximately ten times higher activity compare with CA I.¹⁰⁹ The hCA II is not only a very effective catalyst for interconversion between CO_2 and HCO_3^{110} , it also shows some catalytic versatility, participating in several other hydrolytic processes, which presumably involve nonphysiological substrates¹¹¹. Against the physiologically dominant isoform hCA II, cyclic thioureas (**1–8**) demonstrated K_i s varying from 30.63 ± 7.62 to 76.06 ± 3.15 nM (Table 1). Among which the cyclic thiourea **2** was the best hCA II inhibitor (K_i : 30.63 ± 7.62 nM). Thus, these cyclic thioureas (**1–8**) demonstrated high hCA II inhibition. They are probably interact with the distinct hydrophilic and hydrophobic halves of the CA II active site. The compound **2** [1-(4-(4-Methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone] shown the most inhibition effect with K_i value of 30.63 ± 7.62 nM against cytosolic CA II. CA isoenzymes are physiological very important enzymes. Recently, very intense studies were performed on this subject.
- (3) AChE is localized at cholinergic synapses in vertebrates and regulates neurotransmission through rapid hydrolysis of the

neurotransmitter ACh into choline and acetate. Cholinesterase inhibitors, including carbamates, have gained much attention since they have been successfully used in the treatment of a number of diseases involving cholinergic dysfunction. A number of different types of cholinesterase inhibitors are known and have been found to affect these enzymes in a variety of ways¹¹². In our study, cyclic thioureas (**1–8**) were investigated for their ability to inhibit AChE, which was the primary cholinesterase in the

Table 3. 1,1-Diphenyl-2-picrylhydrazyl (DPPH•) radical scavenging, and ferrous ion (Fe^{2+}) chelating activities of cyclic thioureas (**1–8**).

Antioxidants	DPPH• scavenging		Metal chelating	
	IC ₅₀	r ²	IC ₅₀	r ²
BHA	30.13	0.9622	21.01	0.9622
BHT	40.76	0.9881	31.50	0.9830
α-Tocopherol	28.87	0.9924	15.40	0.9932
Trolox	21.65	0.9686	11.01	0.9797
1	86.62	0.9743	43.31	0.9638
2	173.35	0.9889	79.02	0.9924
3	164.48	0.9628	100.01	0.9921
4	69.30	0.9760	53.31	0.9896
5	76.15	0.9938	36.47	0.9968
6	230.87	0.9718	34.65	0.9826
7	138.60	0.9833	69.30	0.9722
8	144.37	0.9911	33.02	0.9791
EDTA	–	–	11.36	0.9888

Table 1. Human carbonic anhydrase isoenzymes I and II, AChE and BChE enzymes inhibition values of compounds **1–8**.

Compounds	IC ₅₀ (nM)						K _i (nM)					
	hCA I	r ²	hCA II	r ²	AChE	r ²	BChE	r ²	hCA I	hCA II	AChE	BChE
1	61.38	0.9754	99.71	0.9825	13.81	0.9882	49.74	0.9932	52.35 ± 7.31	55.22 ± 1.05	7.41 ± 12.2	22.44 ± 5.71
2	66.18	0.9613	33.83	0.9819	14.31	0.9683	18.41	0.9521	77.68 ± 3.69	30.63 ± 7.62	6.35 ± 23.3	8.02 ± 1.68
3	69.23	0.9820	65.51	0.9636	16.76	0.9385	23.29	0.9770	47.53 ± 6.49	54.18 ± 2.01	7.18 ± 14.1	8.37 ± 1.98
4	55.44	0.9788	68.28	0.9757	14.36	0.9620	29.35	0.9965	50.67 ± 6.45	53.87 ± 2.38	8.83 ± 6.54	6.76 ± 0.59
5	82.01	0.9760	78.75	0.9468	22.58	0.9525	43.88	0.9908	74.06 ± 8.18	56.52 ± 1.59	16.13 ± 56.1	15.53 ± 1.71
6	79.11	0.9800	96.25	0.9476	16.44	0.9904	30.13	0.9736	50.49 ± 8.56	71.27 ± 2.18	11.57 ± 13.4	9.55 ± 3.69
7	74.67	0.9766	80.39	0.9735	13.13	0.9795	43.91	0.9965	47.40 ± 4.43	76.06 ± 3.15	6.11 ± 9.32	15.68 ± 3.41
8	63.28	0.9660	71.59	0.9670	9.36	0.9564	23.36	0.9901	66.95 ± 2.26	49.78 ± 1.51	6.17 ± 16.6	14.85 ± 2.79
AZA*	262.50	0.9567	107.61	0.9496	–	–	–	–	289.22 ± 2.60	135.48 ± 4.59	–	–
TAC**	–	–	–	–	23.84	0.9738	46.13	0.9643	–	–	16.27 ± 42.9	22.49 ± 7.59

*Acetazolamide (AZA) was used as a standard inhibitor for both hCA I and II isoenzymes.
**Tacrine (TAC) was used as a standard inhibitor for AChE and BChE enzymes.

Table 2. Fe^{3+} and Cu^{2+} reducing abilities of cyclic thioureas **1–8**.

a	Fe^{3+} - Fe^{2+} reducing		Cu^{2+} - Cu^{+} reducing	
	λ ₇₀₀	r ²	λ ₄₅₀	r ²
BHA*	2.046 ± 0.039	0.9722	2.126 ± 0.004	0.9870
BHT*	1.398 ± 0.007	0.9718	1.709 ± 0.003	0.9822
α-Tocopherol*	1.715 ± 0.014	0.9981	1.202 ± 0.009	0.9940
Trolox*	1.266 ± 0.011	0.9828	1.177 ± 0.014	0.9917
1	0.816 ± 0.006	0.9683	0.507 ± 0.011	0.9918
2	0.138 ± 0.006	0.9924	0.123 ± 0.003	0.9644
3	0.126 ± 0.004	0.9889	0.109 ± 0.003	0.9588
4	0.671 ± 0.009	0.9877	0.768 ± 0.017	0.9921
5	0.806 ± 0.014	0.9938	0.479 ± 0.003	0.9787
6	0.166 ± 0.006	0.9880	0.137 ± 0.004	0.9910
7	0.192 ± 0.005	0.9944	0.125 ± 0.003	0.9838
8	0.153 ± 0.005	0.9911	0.105 ± 0.004	0.9958

*They were used as reference antioxidant molecules.

body. According to our data, inhibitory effects of these cyclic thioureas (**1–8**) revealed a significant elevation in the case of AChE. AChE inhibitors inhibit the AChE from breaking down ACh, thereby increasing both the level and duration of action of the neurotransmitter ACh. Generally, these compounds showed higher inhibition and higher lipophilicity. Considering the results, all cyclic thioureas (**1–8**) expressed significantly higher inhibition activity. All of cyclic thioureas (**1–8**) derivatives had significantly higher AChE inhibitory activity than that of standard AChE inhibitors such as Tacrine. Furthermore, the K_i values of cyclic thioureas (**1–8**) and standard compound (tacrine) are summarized in Table 1. As can be seen in the results obtained from Table 1, AChE was effectively inhibited by cyclic thioureas (**1–8**), with K_i values in the range of 6.11 ± 9.32 to 16.13 ± 56.1 nM. However, all of cyclic thioureas (**1–8**) had almost similar inhibition profiles. The most active one is 1-(4-(2-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)ethanone (**7**) and showed a K_i value of 6.11 ± 9.32 nM. These results clearly indicate that newly synthesized compounds as well as future similar derivatives may function as drugs for the treatment of AD.

- (4) BChE is the major ACh hydrolyzing enzyme in peripheral mammalian systems. It can either reside in the circulation or adhere to cells and tissues and protect them from anticholinesterases, including insecticides and poisonous nerve gases. Some cholinesterase inhibitors such as rivastigmine and phenserine readily cross the blood-brain barrier to inhibit cholinesterases in the central nervous system, leading to improved cognition in dementias¹¹³. It is well known phenothiazines are known to inhibit cholinesterases, especially BChE¹¹⁴. In the present study, cyclic thioureas (**1–8**) inhibited BChE in ranging of 6.76 ± 0.59 – 22.44 ± 5.71 nM. Cyclic thiourea (**6**) was the best BChE inhibitor (K_i : 6.76 ± 0.59 nM). However, all cyclic thioureas (**1–8**) demonstrated higher BChE inhibition activity than that of Tacrine (K_i : 22.49 ± 7.59 nM).
- (5) Reducing capability of cyclic thioureas (**1–8**) was evaluated by reduction of $\text{Fe}_4[(\text{CN})_6]_3$ to $\text{Fe}_4[(\text{CN})_6]_2$ ¹¹⁵. In this technique, the presence of reductants would result in the reduction of ferric ions (Fe^{3+}) to ferrous ions (Fe^{2+})¹¹⁶. Addition of free Fe^{3+} to the reduced molecule brings about the formation of intensive Perl's Prussian blue complex, $\text{Fe}_4[\text{Fe}(\text{CN})_6]_3$, which has a strong absorbance at 700 nm¹¹⁷. Fe^{3+} reducing assay gets advantage of an electron chain reaction where a ferric salt is utilized as an oxidant¹¹⁸. In addition, the yellow color of the tested mixture changes into diverse tons of green and blue by the ability of the compounds. However, the effective reducing ability was only demonstrated by cyclic thioureas, which possesses phenolic hydroxyl group in their scaffold (**1**, **4** and **5**). Cu^{2+} reducing capability of cyclic thioureas (**1–8**) and positive controls at the same concentration (30 $\mu\text{g/mL}$) showed the following order: BHA (2.046 ± 0.039 ; r^2 : 0.9722) > α -Tocopherol (1.715 ± 0.014 ; r^2 : 0.9981) > BHT (1.398 ± 0.007 ; r^2 : 0.9718) > Trolox (1.266 ± 0.011 ; r^2 : 0.9828) > **1** (0.816 ± 0.006 ; r^2 : 0.9683) \approx **5** (0.806 ± 0.014 ; r^2 : 0.9938) > **4** (0.671 ± 0.009 ; r^2 : 0.9877) (Table 2).
- (6) The CUPRAC method is a rapid, simple, cost-effective, selective, steady and versatile antioxidant assay useful for a wide variety of phenolic compounds. CUPRAC reactions are essentially complete within 30 min. Cu^{2+} reducing power of cyclic thioureas (**1–8**) and positive controls are shown in Table 2. A positive relationship was found between Cu^{2+} reducing power and different concentration of cyclic thioureas (**1–8**). It was detected that Cu^{2+} reducing capacity

of these compounds was addicted to different concentration (10–30 $\mu\text{g/mL}$). Cu^{2+} reducing capability of cyclic thioureas (**1–8**) and positive controls at the same concentration (30 $\mu\text{g/mL}$) showed the following order: BHA (2.126 ± 0.004 ; r^2 : 0.9870) > BHT (1.709 ± 0.003 ; r^2 : 0.9822) > α -Tocopherol (1.202 ± 0.009 ; r^2 : 0.9940) \approx Trolox (1.177 ± 0.014 ; r^2 : 0.9917) > **4** (0.768 ± 0.017 ; r^2 : 0.9921) > **1** (0.507 ± 0.011 ; r^2 : 0.9918) \approx **5** (0.479 ± 0.003 ; r^2 : 0.9787). There was a positive control between Fe^{3+} and Cu^{2+} reducing abilities.

- (7) DPPH test is generally used as the substrate to gauge free radical scavenging effectiveness of antioxidant molecules¹¹⁹. It is based on the reduction of a DPPH solution in alcohol in the source of a hydrogen-donating antioxidant, owing to the formation of non-radical form DPPH-H by the reaction¹²⁰. Cyclic thioureas (**1–8**) have the ability to reduce steady radical DPPH to yellow-colored DPPH-H. Table 3 defines a crucial decrement ($p < 0.01$) in the concentration of DPPH radical owing to the scavenging capability of cyclic thioureas (**1–8**) and reference radical scavenging agents like Trolox, α -Tocopherol, BHT and BHA. IC_{50} values were found as 21.65 $\mu\text{g/mL}$ (0.9686) for trolox, 28.87 $\mu\text{g/mL}$ (0.9924) for α -Tocopherol, 30.13 $\mu\text{g/mL}$ (0.9622) for BHA, 40.76 $\mu\text{g/mL}$ (0.9881) for BHT, 69.30 $\mu\text{g/mL}$ (0.9760) for **4**, 76.15 $\mu\text{g/mL}$ (0.9938) for **5**, and 86.62 $\mu\text{g/mL}$ (0.9743) for **1**. A lower EC_{50} value showed a higher DPPH radical scavenging activity¹²¹. DPPH exposed an absorbance at 517 nm, which vanished after acceptance of an electron or hydrogen radical from an antioxidant compound to become a steadier diamagnetic molecule¹²².
- (8) On the other hand, cyclic thioureas (**1–8**) had also effective Fe^{2+} ions chelating effect. The distinction between different concentrations of cyclic thioureas (**1–8**) (10–30 $\mu\text{g/mL}$) and the control value was fixed to be statistically important ($p < 0.01$). Furthermore, it is found that IC_{50} values for compounds (**1–8**) varied between 33.02–100.01 $\mu\text{g/mL}$ (Table 3). Whereas, IC_{50} values belonging to Fe^{2+} ions chelating capacity of positive controls like BHT, BHA, α -Tocopherol, Trolox, and was found in ranging from 11.01 $\mu\text{g/mL}$ to 31.50 $\mu\text{g/mL}$. A lower EC_{50} value reflects a higher Fe^{2+} ions binding activity. These results clearly introduce that Fe^{2+} ions chelating effect of cyclic thioureas (**1–8**) was close to trolox, α -tocopherol, BHA and BHT. Fe^{2+} ions are the most efficient pro-oxidants in pharmacology systems and food. Ferrozine can create complexes with Fe^{2+} . In the presence of Fe^{2+} chelating compounds, Ferrozine- Fe^{2+} complex formation is a broken down, resulting in a decrease in the red color of Ferrozine- Fe^{2+} complex¹²³.

Conclusion

The cyclic thioureas (**1–8**) used in the present study demonstrated effective inhibition profiles against hCA isoforms, AChE and BChE enzymes. Additionally, these compounds demonstrated effective antioxidant activities using by different bioassays. These compounds identified their potential CA isoenzymes, and AChE and BChE enzyme inhibitors. In this study, nanomolar level of K_i values was observed for all cyclic thioureas (**1–8**) and these compounds can be selective inhibitor of both cytosolic CA I and II isoenzymes and AChE and BChE enzymes. Also, they can be used as novel antioxidants in applications including pharmaceutical industry.

Declaration of interest

The authors have declared no conflict of interest.

IG and SA would like to extend his sincere appreciation to the Research Chairs Program at King Saud University for funding this research.

References

- Liu X, Lu M, Lu T. An efficient protocol for the synthesis of 3,4-dihydropyrimidine-2-(1H)-ones catalyzed by functionalized ionic liquid [DDPA][HSO₄]. *Chiang Mai J Sci* 2011;38:263–9. [Patternmatch].
- Atwal KS, Rovnyak GC, O'Reilly BC, et al. 4-dihydropyrimidines. Synthesis of selectively functionalized 2-hetero-1,4- dihydropyrimidines. *J Org Chem* 1989;54:5898–907.
- Akdemir A, Güzel-Akdemir O, Karalı N, Supuran CT. Isatin analogs as novel inhibitors of *Candida* spp. β -carbonic anhydrase enzymes. *Bioorg Med Chem* 2016;24:1648–52.
- Artunç T, Çetinkaya Y, Göçer H, et al. Synthesis of 4-[2-(3,4-dimethoxybenzyl)cyclopentyl]-1,2-dimethoxybenzene derivatives and evaluations of their carbonic anhydrase isoenzymes inhibitory effects. *Chem Biol Drug Des* 2016;87:594–607.
- Taslimi P, Gülçin İ, Öztaşkın N, et al. The effects of some bromophenols on human carbonic anhydrase isoenzymes. *J Enzyme Inhib Med Chem* 2016;31:603–7.
- Carta F, Supuran CT. Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005–2013). *Expert Opin Ther Pat* 2013;23:681–91.
- Del Prete S, De Luca V, Supuran CT, Capasso C. Protonography, a technique applicable for the analysis of η -carbonic anhydrase activity. *J Enzyme Inhib Med Chem* 2015;30:920–4.
- Gül Hİ, Kucukoglu K, Yamali C, et al. Synthesis of 4-(2-substituted hydrazinyl)benzenesulfonamides and their carbonic anhydrase inhibitory effects. *J Enzyme Inhib Med Chem* 2016;31:568–73.
- Del Prete S, Vullo D, De Luca V, et al. Comparison of the sulfonamide inhibition profiles of the α -, β - and γ -carbonic anhydrases from the pathogenic bacterium. *Bioorg Med Chem Lett* 2016;26:1941–6.
- Gocer H, Aslan A, Gülçin İ, Supuran CT. Spiroisnaphthalenes effectively inhibit carbonic anhydrase. *J Enzyme Inhib Med Chem* 2016;31:503–7.
- Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. *Expert Opin Ther Pat* 2013;23:693–704.
- Gocer H, Topal F, Topal M, et al. Acetylcholinesterase and carbonic anhydrase isoenzymes I and II inhibition profiles of taxifolin. *J Enzyme Inhib Med Chem* 2016;31:441–7.
- Taslimi P, Gulcin İ, Ozgeris B, et al. The human carbonic anhydrase isoenzymes I and II (hCA I and II) inhibition effects of trimethoxyindane derivatives. *J Enzyme Inhib Med Chem* 2016;31:152–7.
- Özgeris B, Göksu S, Polat Köse L, et al. Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds. *Bioorg Med Chem* 2016;24:2318–29.
- Ceruso M, Antel S, Scozzafava A, Supuran CT. Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors. *J Enzyme Inhib Med Chem* 2016;31:205–11.
- Scozzafava A, Kalın P, Supuran CT, et al. The impact of hydroquinone on acetylcholine esterase and certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). *J Enzyme Inhib Med Chem* 2015;30:941–6.
- Akincioğlu A, Akincioğlu H, Gülçin İ, et al. Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: novel sulfamoylcarbamates and sulfamides derived from acetophenones. *Bioorg Med Chem* 2015;23:3592–602.
- Aksu K, Nar M, Taç M, et al. Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine. *Bioorg Med Chem* 2013;21:2925–31.
- Yıldırım A, Atmaca U, Keskin A, et al. N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II. *Bioorg Med Chem* 2015;23:2598–605.
- Ameis HM, Drenckhan A, Freytag M, et al. Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma. *J Enzyme Inhib Med Chem* 2016;31:404–9.
- Boztaş M, Çetinkaya Y, Topal M, et al. Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxy-bromophenol derivatives incorporating cyclopropane moieties. *J Med Chem* 2015;58:640–50.
- De Simone G, Alterio V, Supuran CT. Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors. *Expert Opin Drug Disc* 2013;8:793–810.
- Scozzafava A, Passaponti M, Supuran CT, Gülçin İ. Carbonic anhydrase inhibitors: guaiacol and catechol derivatives effectively inhibit certain human carbonic anhydrase isoenzymes (hCA I, II, IX, and XII). *J Enzyme Inhib Med Chem* 2015;30:586–91.
- Göçer H, Akincioğlu A, Göksu S, et al. Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoyl-carbamates. *J Enzyme Inhib Med Chem* 2015;30:316–20.
- Supuran CT. Carbonic anhydrases. *Bioorg Med Chem* 2013;21:1377–8.
- Arabaci B, Gülçin İ, Alwasel S. Capsaicin: a potent inhibitor of carbonic anhydrase isoenzymes. *Molecules* 2015;19:10103–14.
- Del Prete S, Vullo D, Fisher GM, et al. Discovery of a new family of carbonic anhydrases in the malaria pathogen *Plasmodium falciparum*-the η -carbonic anhydrases. *Bioorg Med Chem Lett* 2014;24:4389–96.
- Akbaba Y, Bastem E, Topal F, et al. Synthesis and carbonic anhydrase inhibitory effects of novel sulfamides derived from 1-aminoindanes and anilines. *Arch Pharm (Weinheim)* 2014;347:950–7.
- Göksu S, Naderi A, Akbaba Y, et al. Carbonic anhydrase inhibitory properties of novel benzylsulfamides using molecular modeling and experimental studies. *Bioorg Chem* 2014;56:75–82.
- Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81.
- Supuran CT, Capasso C. The η -class carbonic anhydrases as drug targets for antimalarial agents. *Expert Opin Ther Targets* 2015;19:551–63.
- Güney M, Coşkun A, Topal F, et al. Oxidation of cyanobenzocycloheptatrienes: synthesis, photooxygenation reaction and carbonic anhydrase isoenzymes inhibition properties of some new benzotropone derivatives. *Bioorg Med Chem* 2014;22:3537–43.
- Topal M, Gülçin İ. Rosmarinic acid: a potent carbonic anhydrase isoenzymes inhibitor. *Türk J Chem* 2014;38:894–902.
- Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? *J Enzyme Inhib Med Chem* 2016;31:345–60.
- Çetinkaya Y, Göçer H, Gülçin İ, Menzek A. Synthesis and carbonic anhydrase isoenzymes inhibitory effects of brominated diphenyl-methanone and its derivatives. *Arch Pharm (Weinheim)* 2014;347:354–9.
- Bozdağ M, Carta F, Vullo D, et al. Dithiocarbamates with potent inhibitory activity against the *Saccharomyces cerevisiae* β -carbonic anhydrase. *J Enzyme Inhib Med Chem* 2016;31:132–6.
- Akincioğlu A, Topal M, Gülçin İ, Göksu S. Novel sulfamides and sulfonamides incorporating tetralin scaffold as carbonic anhydrase and acetylcholine esterase inhibitors. *Arch Pharm* 2014;347:68–76.
- Çetinkaya Y, Göçer H, Göksu S, Gülçin İ. Synthesis and carbonic anhydrase isoenzymes I and II inhibitory effects of novel benzylamine derivatives. *J Enzyme Inhib Med Chem* 2014;29:168–74.
- Topal M, Gocer H, Topal F, et al. Antioxidant, antiradical and anticholinergic properties of cynarin purified from the illyrian thistle (*Onopordum illyricum* L.). *J Enzyme Inhib Med Chem* 2016;31:266–75.
- Polat Köse L, Gülçin İ, Gören AC, et al. LC-MS/MS analysis, antioxidant and anticholinergic properties of galanga (*Alpinia officinarum* Hance) rhizomes. *Ind Crops Prod* 2015;74:712–21.
- Öztaşkın N, Çetinkaya Y, Taslimi P, et al. Antioxidant and acetylcholinesterase inhibition properties of novel bromophenol derivatives. *Bioorg Chem* 2015;60:49–57.
- Gülçin İ, Scozzafava A, Supuran CT, et al. The effect of caffeic acid phenethyl ester (CAPE) metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione S-transferase, lactoperoxidase and carbonic anhydrase isoenzymes I, II, IX and XII. *J Enzyme Inhib Med Chem* 2015. [Epub ahead of print]. doi: <http://dx.doi.org/10.3109/14756366.2015.1094470>.
- Gülçin İ, Scozzafava A, Supuran CT, et al. Rosmarinic acid inhibits some metabolic enzymes including glutathione S-transferase, lactoperoxidase, acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase isoenzymes. *J Enzyme Inhib Med Chem* 2015. [Epub ahead of print]. doi: <http://dx.doi.org/10.3109/14756366.2015.1135914>.

44. Yılmaz S, Akbaba Y, Özgeriş B, et al. Synthesis and inhibitory properties of some carbamates on carbonic anhydrase and acetylcholine esterase. *J Enzyme Inhib Med Chem* 2016. [Epub ahead of print]. doi: <http://dx.doi.org/10.3109/14756366.2016.1149477>.
45. Zhou G, Wang F, Wang H, et al. Colorimetric and fluorometric assays based on conjugated polydiacetylene supramolecules for screening acetylcholinesterase and its inhibitors. *ACS Appl Mater Interfaces* 2013;5:3275–80.
46. Sujayev A, Garibov E, Taslimi P, et al. Synthesis of some tetrahydropyrimidine-5-carboxylates, determination of their metal chelating effects and inhibition profiles against acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase. *J Enzyme Inhib Med Chem* 2016. [Epub ahead of print]. doi: <http://dx.doi.org/10.3109/14756366.2016.1156104>.
47. Aksu K, Topal F, Gulcin İ, et al. Acetylcholinesterase inhibitory and antioxidant activities of novel symmetric sulfamides derived from phenethylamines. *Arch Pharm* 2015;348:446–55.
48. Mao F, Li J, Wei H, et al. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer's disease. *J Enzyme Inhib Med Chem* 2015;30:995–1001.
49. Göçer H, Akıncioğlu A, Öztürk N, et al. Synthesis, antioxidant, and antiacetylcholinesterase activities of sulfonamide derivatives of dopamine-related compounds. *Arch Pharm (Weinheim)* 2013;346:783–92.
50. Gülçin İ. Antioxidant properties of resveratrol: a structure-activity insight. *Innov Food Sci Emerg* 2010;11:210–18.
51. Gülçin İ. Antioxidant activity of L-adrenaline: a structure-activity insight. *Chem Biol Interact* 2009;179:71–80.
52. Köksal E, Gülçin İ, Öztürk Sarıkaya SB, Bursal E. On the in vitro antioxidant activity of silymarin. *J Enzyme Inhib Med Chem* 2009;24:395–405.
53. Çakmakçı S, Topdaş EF, Kalın P, et al. Antioxidant capacity and functionality of oleaster (*Elaeagnus angustifolia* L.) flour and crust in a new kind of fruity ice cream. *Int J Food Sci Technol* 2015;50:472–81.
54. Sehitoglu MH, Han H, Kalin P, et al. Pistachio (*Pistacia vera* L.) gum: a potent inhibitor of reactive oxygen species. *J Enzyme Inhib Med Chem* 2015;30:264–9.
55. Kalın P, Gülçin İ, Gören AC. Antioxidant activity and polyphenol content of *Vaccinium macrocarpon*. *Rec Nat Prod* 2015;9:496–502.
56. Topal F, Topal M, Gocer H. Antioxidant activity of taxifolin: an activity-structure relationship. *J Enzyme Inhib Med Chem* 2016;31:674–83.
57. Işık M, Korkmaz M, Bursal E, et al. Determination of antioxidant properties of *Gypsophila bitlisensis*. *Int J Pharmacol* 2015;11:366–71.
58. Bursal E, Köksal E, Gülçin İ, et al. Antioxidant activity and polyphenol content of cherry stem (*Cerasus avium* L.) determined by LC-MS/MS. *Food Res Int* 2013;51:66–74.
59. Gülçin İ, Elmastaş M, Aboul-Enein HY. Antioxidant activity of clove oil-A powerful antioxidant source. *Arab J Chem* 2012;5:489–99.
60. Gülçin İ. Antioxidant activity of food constituents: an overview. *Arch Toxicol* 2012;86:345–91.
61. Çetinkaya Y, Göçer H, Menzek A, Gülçin İ. Synthesis and antioxidant properties of (3,4-dihydroxyphenyl)(2,3,4-trihydroxyphenyl)methanone and its derivatives. *Arch Pharm (Weinheim)* 2012;345:323–34.
62. Gülçin İ, Beydemir S, Topal F, et al. Apoptotic, antioxidant and antiradical effects of majdine and isomajdine from *Vinca herbacea* Waldst. and kit. *J Enzyme Inhib Med Chem* 2012;27:587–94.
63. Göçer H, Gülçin İ. Caffeic acid phenethyl ester (CAPE): correlation of structure and antioxidant properties. *Int J Food Sci Nutr* 2011;62:821–5.
64. Bursal E, Gülçin İ. Polyphenol contents and *in vitro* antioxidant activities of lyophilized aqueous extract of kiwifruit (*Actinidia deliciosa*). *Food Res Int* 2011;44:1482–9.
65. Gülçin İ, Topal F, Çakmakçı R, et al. Pomological features, nutritional quality, polyphenol content analysis and antioxidant properties of domesticated and three wild ecotype forms of raspberries (*Rubus idaeus* L.). *J Food Sci* 2011;76:C585–93.
66. Gülçin İ, Topal F, Öztürk Sarıkaya SB, et al. Polyphenol contents and antioxidant properties of medlar (*Mespilus germanica* L.). *Rec Nat Prod* 2011;5:158–75.
67. Köksal E, Bursal E, Dikici E, et al. Antioxidant activity of *Melissa officinalis* leaves. *J Med Plants Res* 2011;5:217–22.
68. Brands M, Endermann R, Gahlmann R, et al. Dihydropyrimidinones a new class of anti-staphylococcal antibiotics. *Bioorg Med Chem Lett* 2003;13:241–5.
69. Wang DC, Guo HM, Qu GR. Efficient, green, solvent-free synthesis of 3,4-dihydropyrimidin-2(1h)-ones via biginelli reaction catalyzed by Cu(NO₃)₂·3H₂O. *Synthetic Commun* 2010;40:1115–22.
70. Hussein WM, Fatahala SS, Mohamed ZM, et al. Synthesis and kinetic testing of tetrahydropyrimidine-2-thione and pyrrole derivatives as inhibitors of the metallo-β-lactamase from *Klebsiella pneumonia* and *Pseudomonas aeruginosa*. *Chem Biol Drug Des* 2012;80:500–5.
71. Li N, Chen XH, Song J, et al. Highly enantioselective organocatalytic biginelli and biginelli-like condensations: reversal of the stereochemistry by tuning the 3,3'-disubstituents of phosphoric acids. *J Am Chem Soc* 2009;131:15301–10.
72. Ahmed B, Khan RA, Habibullah Keshari M. An improved synthesis of biginelli-type compounds via phase-transfer catalysis. *Tetrahedron Lett* 2009;50:2889–92.
73. Liu J, Wu F, Chen L, et al. Evaluation of dihydropyrimidin-(2H)-one analogues and rhodanine derivatives as tyrosinase inhibitors. *Bioorg Med Chem Lett* 2011;21:2376–9.
74. Lacotte P, Puente C, Ambroise Y. Synthesis and evaluation of 3,4-dihydropyrimidin-2(1h)-ones as sodium iodide symporter inhibitors. *Chem Med Chem* 2013;8:104–11.
75. Atasever A, Özdemir H, Gülçin İ, Küfrevioğlu Öİ. One-step purification of lactoperoxidase from bovine milk by affinity chromatography. *Food Chem* 2013;136:864–70.
76. Şentürk M, Gülçin İ, Beydemir Ş, et al. *In vitro* inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. *Chem Biol Drug Des* 2011;77:494–9.
77. Öztürk Sarıkaya SB, Gülçin İ, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of phenolic acids. *Chem Biol Drug Des* 2010;75:515–20.
78. Gülçin İ, Küfrevioğlu Öİ, Oktay M. Purification and characterization of polyphenol oxidase from nettle (*Urtica dioica* L.) and inhibitory effects of some chemicals on enzyme activity. *J Enzyme Inhib Med Chem* 2005;20:297–302.
79. Aydın B, Gülçin İ, Alwasel SH. Purification and characterization of polyphenol oxidase from Hemşin apple (*Malus communis* L.). *Int J Food Propert* 2015;18:2735–45.
80. Öztürk Sarıkaya SB, Sisecioglu M, Cankaya M, et al. Inhibition profile of a series of phenolic acids on bovine lactoperoxidase enzyme. *J Enzyme Inhib Med Chem* 2015;30:479–83.
81. Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. *J Biol Chem* 1967;242:4221–9.
82. Akbaba Y, Akıncioğlu A, Göçer H, et al. Carbonic anhydrase inhibitory properties of novel sulfonamide derivatives of aminoidanes and aminotetralins. *J Enzyme Inhib Med Chem* 2014;29:35–42.
83. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248–54.
84. Lineweaver H, Burk D. The determination of enzyme dissociation constants. *J Am Chem Soc* 1934;56:658–66.
85. Nar M, Çetinkaya Y, Gülçin İ, Menzek A. (3,4-Dihydroxyphenyl)(2,3,4-trihydroxyphenyl)methanone and its derivatives as carbonic anhydrase isoenzymes inhibitors. *J Enzyme Inhib Med Chem* 2013;28:402–6.
86. Ellman GL, Courtney KD, Andres V, Featherston RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961;7:88–95.
87. Gülçin İ, Huyut Z, Elmastaş M, Aboul-Enein HY. Radical scavenging and antioxidant activity of tannic acid. *Arab J Chem* 2010;3:43–53.
88. Gülçin İ, Bursal E, Şehitoğlu HM, et al. Polyphenol contents and antioxidant activity of lyophilized aqueous extract of propolis from Erzurum, Turkey. *Food Chem Toxicol* 2010;48:2227–38.
89. Gülçin İ. Antioxidant activity of eugenol: a structure-activity relationship study. *J Med Food* 2011;14:975–85.
90. Gülçin İ, Kirecci E, Akkemik E, et al. Antioxidant and antimicrobial activities of an aquatic plant: duckweed (*Lemna minor* L.). *Turk J Biol* 2010;34:175–88.

91. Şerbetçi Tohma H, Gülçin İ. Antioxidant and radical scavenging activity of aerial parts and roots of Turkish liquorice (*Glycyrrhiza glabra* L.). *Int J Food Propert* 2010;13:657–71.
92. Balaydın HT, Gülçin İ, Menzek A, et al. Synthesis and antioxidant properties of diphenylmethane derivative bromophenols including a natural product. *J Enzyme Inhib Med Chem* 2010;25:685–95.
93. Gülçin İ, Elias R, Gepdiremen A, et al. Antioxidant activity of bisbenzylisoquinoline alkaloids from *Stephania rotunda*: Cepharanthine and fangchinoline. *J Enzyme Inhib Med Chem* 2010;25:44–53.
94. Talaz O, Gülçin İ, Göksu S, Saracoglu N. Antioxidant activity of 5,10-dihydroindeno[1,2-b]indoles containing substituents on dihydroindeno part. *Bioorg Med Chem* 2009;17:6583–9.
95. Gülçin İ, Elias R, Gepdiremen A, et al. Antioxidant secoiridoids from fringe tree (*Chionanthus virginicus* L.). *Wood Sci Technol* 2009;43:195–212.
96. Ak T, Gülçin İ. Antioxidant and radical scavenging properties of curcumin. *Chem Biol Interact* 2008;174:27–37.
97. Köksal E, Gülçin İ. Antioxidant activity of cauliflower (*Brassica oleracea* L.). *Turk J Agric For* 2008;32:65–78.
98. Gülçin İ, Oktay M, Köksal E, et al. Antioxidant and radical scavenging activities of uric acid. *Asian J Chem* 2008;20:2079–90.
99. Gülçin İ, Tel AZ, Kirecci E. Antioxidant, antimicrobial, antifungal and antiradical activities of *Cyclotrichium niveum* (Boiss.) Manden and Scheng. *Int J Food Propert* 2008;11:450–71.
100. Gülçin İ. Measurement of antioxidant ability of melatonin and serotonin by the DMPD and CUPRAC methods as trolox equivalent. *J Enzyme Inhib Med Chem* 2008;23:871–6.
101. Gülçin İ, Elmastas M, Aboul-Enein HY. Determination of antioxidant and radical scavenging activity of basil (*Ocimum basilicum*) assayed by different methodologies. *Phytother Res* 2007;21:354–61.
102. Gülçin İ. Comparison of in vitro antioxidant and antiradical activities of L-tyrosine and L-Dopa. *Amino Acids* 2007;32:431–8.
103. Gülçin İ, Elias R, Gepdiremen A, Boyer L. Antioxidant activity of lignans from fringe tree (*Chionanthus virginicus* L.). *Eur Food Res Technol* 2006;223:759–67.
104. Elmastaş M, Gülçin İ, Beydemir Ş, et al. A study on the in vitro antioxidant activity of juniper (*Juniperus communis* L.) seeds extracts. *Anal Lett* 2006;39:47–65.
105. Elmastas M, Türkekul İ, Öztürk L, et al. The antioxidant activity of two wild edible mushrooms (*Morchella vulgaris* and *Morchella esculanta*). *Comb Chem High Thr Scr* 2006;9:443–8.
106. Öztürk Sarıkaya SB, Topal F, Şentürk M, et al. In vitro inhibition of α -carbonic anhydrase isozymes by some phenolic compounds. *Bioorg Med Chem Lett* 2011;21:4259–62.
107. Innocenti A, Gülçin İ, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenol natural products effectively inhibit mammalian isoforms I–XV. *Bioorg Med Chem Lett* 2010;20:5050–3.
108. Innocenti A, Öztürk Sarıkaya SB, Gülçin İ, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I–XIV with a series of natural product polyphenols and phenolic acids. *Bioorg Med Chem* 2010;18:2159–64.
109. Şentürk M, Gülçin İ, Daştan A, et al. Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. *Bioorg Med Chem* 2009;17:3207–11.
110. Çoban TA, Beydemir Ş, Gülçin İ, Ekinçi D. The effect of ethanol on erythrocyte carbonic anhydrase isoenzymes activity: an in vitro and in vivo study. *J Enzyme Inhib Med Chem* 2008;23:266–70.
111. Çoban TA, Beydemir Ş, Gülçin İ, Ekinçi D. Morphine inhibits erythrocyte carbonic anhydrase in vitro and in vivo. *Biol Pharm Bull* 2007;30:2257–61.
112. Darvesh S, Darvesh KV, McDonald RS, et al. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. *J Med Chem* 2008;51:4200–12.
113. Debord J, Merle L, Bollinger JC, Dantoine T. Inhibition of butyrylcholinesterase by phenothiazine derivatives. *J Enzyme Inhib Med Chem* 2002;17:197–202.
114. Gülçin İ, Daştan A. Synthesis of dimeric phenol derivatives and determination of in vitro antioxidant and radical scavenging activities. *J Enzyme Inhib Med Chem* 2007;22:685–95.
115. Gülçin İ, Elias R, Gepdiremen A, et al. A comparative study on the antioxidant activity of fringe tree (*Chionanthus virginicus* L.) extracts. *Afr J Biotechnol* 2007;6:410–8.
116. Gülçin İ. Antioxidant and antiradical activities of L-carnitine. *Life Sci* 2006;78:803–11.
117. Köksal E, Bursal E, Gülçin İ, et al. Antioxidant activity and polyphenol content of Turkish thyme (*Thymus vulgaris*) monitored by LC-MS/MS. *Int J Food Propert*. [Epub ahead of print]. doi: <http://dx.doi.org/10.1080/10942912.2016.1168438>.
118. Gülçin İ, Beydemir Ş, Şat İG, Küfrevioğlu Öİ. Evaluation of antioxidant activity of cornelian cherry (*Cornus mas* L.). *Acta Aliment Hung* 2005;34:193–202.
119. Gülçin İ, Alici HA, Cesur M. Determination of in vitro antioxidant and radical scavenging activities of propofol. *Chem Pharm Bull* 2005;53:281–5.
120. Gülçin İ, Mshvildadze V, Gepdiremen A, Elias R. Antioxidant activity of saponins isolated from ivy: alpha-hederin, hederasaponin-C, hederacolchiside-E and hederacolchiside-F. *Planta Med* 2004;70:561–3.
121. Gülçin İ, Küfrevioğlu Öİ, Oktay M, Büyükkuroğlu ME. Antioxidant, antimicrobial, antiulcer and analgesic activities of nettle (*Urtica dioica* L.). *J Ethnopharmacol* 2004;90:205–15.
122. Gülçin İ, Şat İG, Beydemir Ş, et al. Comparison of antioxidant activity of clove (*Eugenia caryophyllata* Thunb) buds and lavender (*Lavandula stoechas* L.). *Food Chem* 2004;87:393–400.
123. Gülçin İ, Şat İG, Beydemir Ş, Küfrevioğlu Öİ. Evaluation of the in vitro antioxidant properties of extracts of broccoli (*Brassica oleracea* L.). *Ital J Food Sci* 2004;16:17–30.